Cite
HARVARD Citation
Kümmel, S. et al. (n.d.). 323PSubcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis. Annals of oncology. p. . [Online].